Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

WT1 Induces Expression of Insulin-like Growth Factor 2 in Wilms' Tumor Cells

WT1 Induces Expression of Insulin-like Growth Factor 2 in Wilms' Tumor Cells The Wilms' tumor suppressor gene WT1 encodes a zinc finger transcription factor, whose expression inhibits the growth of the RM1 Wilms' tumor cell line. Transient transfection of WT1 constructs into 3T3 or 293 cells results in transcriptional repression of a number of cotransfected promoters containing the early growth response gene 1 consensus sequence. We now show that WT1 has properties of a transcriptional activator in RM1 cells, an effect that may be associated with the presence of a mutated p53 gene in these cells. Stable transfection of wild-type WT1 into RM1 cells results in induction of endogenous insulin-like growth factor 2 (IGF2) but not of other previously postulated WT1-target genes. The induction of IGF2 is dramatically enhanced by WT1 mutants encoding an altered transactivation domain. We conclude that IGF2 is a potentially physiological target gene for WT1 and that its induction may contribute to the growth-stimulating effects of WT1 variants. 1 This grant was supported by NIH Grants CA 37887 (to A. J. G.) and CA 58596 (to D. A. H.). 2 To whom requests for reprints should be addressed, at Massachusetts General Hospital Cancer Center, CNY 7, Building 149, 13th Street, Charlestown, MA 02129. Phone: (617) 726-7805; Fax: (617) 726-5637. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Research American Association of Cancer Research

WT1 Induces Expression of Insulin-like Growth Factor 2 in Wilms' Tumor Cells

WT1 Induces Expression of Insulin-like Growth Factor 2 in Wilms' Tumor Cells

Cancer Research , Volume 55 (20): 4540 – Oct 15, 1995

Abstract

The Wilms' tumor suppressor gene WT1 encodes a zinc finger transcription factor, whose expression inhibits the growth of the RM1 Wilms' tumor cell line. Transient transfection of WT1 constructs into 3T3 or 293 cells results in transcriptional repression of a number of cotransfected promoters containing the early growth response gene 1 consensus sequence. We now show that WT1 has properties of a transcriptional activator in RM1 cells, an effect that may be associated with the presence of a mutated p53 gene in these cells. Stable transfection of wild-type WT1 into RM1 cells results in induction of endogenous insulin-like growth factor 2 (IGF2) but not of other previously postulated WT1-target genes. The induction of IGF2 is dramatically enhanced by WT1 mutants encoding an altered transactivation domain. We conclude that IGF2 is a potentially physiological target gene for WT1 and that its induction may contribute to the growth-stimulating effects of WT1 variants. 1 This grant was supported by NIH Grants CA 37887 (to A. J. G.) and CA 58596 (to D. A. H.). 2 To whom requests for reprints should be addressed, at Massachusetts General Hospital Cancer Center, CNY 7, Building 149, 13th Street, Charlestown, MA 02129. Phone: (617) 726-7805; Fax: (617) 726-5637.

Loading next page...
 
/lp/american-association-of-cancer-research/wt1-induces-expression-of-insulin-like-growth-factor-2-in-wilms-tumor-wo5bMzzOCX

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Association of Cancer Research
Copyright
Copyright © 1995 by the American Association for Cancer Research.
ISSN
0008-5472
Publisher site

Abstract

The Wilms' tumor suppressor gene WT1 encodes a zinc finger transcription factor, whose expression inhibits the growth of the RM1 Wilms' tumor cell line. Transient transfection of WT1 constructs into 3T3 or 293 cells results in transcriptional repression of a number of cotransfected promoters containing the early growth response gene 1 consensus sequence. We now show that WT1 has properties of a transcriptional activator in RM1 cells, an effect that may be associated with the presence of a mutated p53 gene in these cells. Stable transfection of wild-type WT1 into RM1 cells results in induction of endogenous insulin-like growth factor 2 (IGF2) but not of other previously postulated WT1-target genes. The induction of IGF2 is dramatically enhanced by WT1 mutants encoding an altered transactivation domain. We conclude that IGF2 is a potentially physiological target gene for WT1 and that its induction may contribute to the growth-stimulating effects of WT1 variants. 1 This grant was supported by NIH Grants CA 37887 (to A. J. G.) and CA 58596 (to D. A. H.). 2 To whom requests for reprints should be addressed, at Massachusetts General Hospital Cancer Center, CNY 7, Building 149, 13th Street, Charlestown, MA 02129. Phone: (617) 726-7805; Fax: (617) 726-5637.

Journal

Cancer ResearchAmerican Association of Cancer Research

Published: Oct 15, 1995

There are no references for this article.